FDA approval BIC LEN HIV Drug Bixlenvo Gilead

The U.S. FDA has approved Gilead's Bixlenvo, a new HIV drug combining bictegravir and lenacapavir, offering a potentially more effective treatment option for people living with HIV.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 28 Aug 2026 and 31 Aug 2026.